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Antiviral therapyComprehensive analysis of mammalian transcriptomes has surprisingly revealed that a major fraction of
the RNAs produced by mammalian cells and tissues is comprised of long non-coding RNAs (lncRNAs).
Such RNAs were previously disregarded as useless, but recent functional studies have revealed that they
have multiple regulatory functions. A large subset of these lncRNAs are antisense to protein-coding
genes; such RNAs are particularly attractive to researchers because their functions are better understood
than other lncRNAs and their action can be easily modulated and engineered by modifying the antisense
region. We discuss various aspects of regulation by antisense RNAs and other small nucleic acids and the
challenges to bring these technologies to gene therapy. Despite several remaining issues related to deliv-
ery, RNA stability, side effects, and toxicity, the ﬁeld is moving quickly towards future biotechnological
and health applications. Therapies based on lncRNAs may be the key to increased cell-speciﬁcity of future
gene therapies.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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One of the surprises of genomics has been the discovery that
mammalian genomes produce a large amount of non-codingRNA. Apart from the production of small RNAs, such as microRNAs
(miRNAs), which often function as negative regulators of RNA sta-
bility or translation, there are many long non-coding RNAs (lncR-
NAs) that have been well categorized both in mouse [1] and
human [2–4]. Results of large-scale analyses suggest a striking
but inconvenient truth: there are more non-coding RNAs than
the 20,000 protein-coding genes. The FANTOM3 project, by using
physical cDNA clone analysis alone, identiﬁed more than 23,000
lncRNAs [1]. The GENCODE project (release 20), as part of the
ENCODE project [5], identiﬁed almost 24,000 loci producing lncR-
NAs, but the total census of non-coding RNAs may be above
37,000 if miRNAs, RNA from processed pseudogene transcripts,
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lncRNAs may still rise if next-generation sequencing studies focus
on cell types that are not yet completely characterized. For exam-
ple, in human embryonic stem (ES) cells and induced pluripotent
stem cells (iPSCs), deep sequencing of cytoplasmic and nuclear
transcripts has uncovered more than 3000 lncRNAs that were not
previously identiﬁed in the GENCODE catalogue, including a large
fraction of RNAs derived from long terminal repeats (LTRs) and
other retrotransposon elements [6]. The function of the majority
of lncRNAs is still unknown; however, whenever the function has
been determined, lncRNAs show a remarkable diversity of function
and mechanisms of action in various cell compartments.
After synthesis, a large number of lncRNAs never leave the
nucleus, which makes this organelle a large source of uncharacter-
ized lncRNAs [6,7]. A fraction of these lncRNAs closely interact with
the chromatin and help to direct the epigenome. For instance, lncR-
NAs can mediate the interaction between polycomb repressive
complex and target genes in ES cells [8], or mediate X-chromosome
inactivation [9] by physically causing chromatin condensation
around interacting regions in cis on X-chromosome [10,11]. Alter-
natively, lncRNAs can act in trans: e.g., HOTAIR, whose mis-expres-
sion is associated with cancer [12]. To further complicate the
interpretation and analysis of lncRNAs, active enhancers also pro-
duce lncRNAs, often called eRNAs [6,13], whose function is mostly
unknown. At least in some cases, eRNAs could be essential struc-
tural molecules that promote nuclear interactions through the
multi-protein complex called Mediator, thus enhancing the set of
potential regulatory lncRNAs [14]. LncRNAs can also have other
structural functions in the nucleus: for instance, NEAT1 is an essen-
tial RNA component of structures known as paraspeckles [15].
There are numerous cases where lncRNAs are processed to produce
smaller RNAs, which have various regulatory functions, including
not only miRNAs [16] and small nucleolar RNAs (commonly known
as snoRNAs) [17] but also other classes of small RNAs [18,19]. Due
to space limitations we cannot extensively review all aspects of
RNA processing and we apologize for not citing some important
works of colleagues: please see other reviews [20–23] for extensive
discussions of lncRNAs and their processing.
Antisense transcripts [24] are a broad and very important com-
ponent of the non-coding transcriptome. The mechanisms of action
and regulation of antisense lncRNAs are somehow better under-
stood than those of other lncRNAs. Because antisense sequences
can easily be designed, lncRNA action based on sense-antisense
transcript pairing is highly ﬂexible in principle. Accordingly, we
will focus on the biology and current applications of antisense
lncRNAs, and how these transcripts could be used for future
therapies.2. Role of some lncRNA in diseases
Some antisense lncRNAs can positively regulate transcription
[25,26]. A prime example is the regulation of the gene encoding
b-secretase 1 (BASE1) (also known as b-site amyloid precursor pro-
tein-cleaving enzyme), which is implicated in the pathogenesis of
Alzheimer’s disease. Transcription of BASE1 is positively regulated
by its noncoding antisense transcript (BASE1-AS). Knockdown
experiments with small interfering RNA (siRNA) against BASE1-
AS RNA caused reduction of amyloid b (Ab) 1–40 and Ab 1–42 pro-
tein production in human SH-SY5Y cells. These results suggest that
BASE1-AS transcript is positive regulator of transcription of the
coding gene. In vivo experiments showed that 14 days continuous
treatment with siRNA targeting BASE1-AS transcript reduces the
BACE1 mRNA expression level in mouse brain regions (cortex, stri-
atum, dorsal hippocampus, and ventral hippocampus). Cell stress
with high temperature, serum starvation, Ab 1–42 accumulation,exposure to H2O2, or treatment with a high glucose concentration
caused a 30–130% increase in BACE1-AS levels associated with a
20–60% increase in BACE1mRNA levels. When BACE1-AS transcript
levels in the cerebellum, hippocampus, entorhinal cortex, and
superior frontal gyrus were compared between Alzheimer’s dis-
ease patients and control subjects, the BACE1-AS levels were ele-
vated in Alzheimer’s disease subjects by up to six fold, with an
average of about two fold across all brain regions [25]. This study
is particularly remarkable because the lncRNA expression level
can positively control the mRNA expression level.
Some of the mechanisms of gene regulation based on sense-
antisense pairing in the nucleus appear to involve transcriptional
interference [27] or the siRNA pathway. For instance, in the
nucleus, argonaute (AGO) proteins, a part of the RNA-induced
silencing complex (RISC), are involved both in speciﬁc transcrip-
tional activation and repression [28], suggesting broad involve-
ment of the siRNA machinery on the chromatin. Importantly,
although AS RNAs are commonly believed to be mostly negative
regulators of sense mRNA counterparts [25], there are many more
mechanisms of action, many of which are not yet fully understood.
Apart from regulating transcript stability, antisense lncRNAs
can regulate transcription initiation [24,27]. This phenomenon
could be used in future AS RNA therapies: in fact, inhibition and
degradation of natural antisense transcripts (NATs) could upregu-
late some speciﬁc mRNAs for therapeutic purposes. The group
led by Claes Wahlestedt found that inhibition of the NAT of the
gene for brain-derived neurotrophic factor (BDNF) increases the
level of the sense mRNA transcript and BDNF protein expression,
leading to neuronal outgrowth and differentiation in vitro and
in vivo. In a follow-up study, the same group investigated two addi-
tional RNAs, which are antisense to the mRNAs encoding glial-
derived neurotrophic factor (GDNF) and ephrin receptor B2
(EPHB2). Inhibition of these NATs resulted in increased sense
mRNA transcript levels [29], showing that this is a general phe-
nomenon. The application of these approaches for increasing pro-
tein production is becoming recognized as important for human
therapy. Accordingly, the company OPKO-CURNA in USA is exploit-
ing this approach, which was named ‘‘Inhibition of Antisense Tran-
scripts to Upregulate its Sense mRNA’’. These new RNAs, named
AntagoNATs, are designed to target the NAT region overlapping
the mRNA and thus inhibit the sense-antisense RNA pairing
(Fig. 1A).
Since many antisense and other lncRNAs are regulated by cellu-
lar stress, it is very important to understand their dynamic expres-
sion and regulation when cells or tissues are under stress,
including during heat shock [30] or immune challenge [31].
Genetic mutations can affect antisense regulation. For example,
a-thalassemia is a disorder caused by reduced production of func-
tional globins due to gene mutation. In particular cases, the muta-
tion increases expression of an antisense transcript, called LUC7L,
which induces transcriptional silencing of globin genes by methyl-
ation of the CpG island [32].3. SINEUPs: surprising AS RNAs that enhance translation
Reduction in the expression of the UCHL1 gene (also called
PARK5), is positively correlated with familial Parkinson’s disease
[33]. A surprising novel mechanism of sense-antisense action came
from the study of AS Uchl1 RNA (AS-Uchl1) in mouse [34]. Large-
scale analysis of full-length cDNA sequences by the FANTOM3 con-
sortium reported widespread sense-antisense transcription (>72%
of identiﬁed genes in mouse) [24]. Using the FANTOM3 cDNA
clones, Carrieri et al. investigated the functional role of AS RNAs,
including AS-Uchl1, in the mouse dopaminergic neuronal cell-line,
MN9D. AS-Uchl1 overlaps the 50 untranslated region (UTR) and
Fig. 1. Novel RNA therapeutics. (A) AntagoNATs: inhibitors of natural antisense transcripts (antagoNATs) are designed against non-coding AS RNAs in the region that overlaps
with mRNA, causing the mRNA to be overexpressed with resultant up-regulation at the protein level. (B) SINEUP: a SINE element is present in the antisense RNA (AS RNA).
When the mRNA and AS RNA overlap, the AS RNA can work as a guide for mRNA translation, thereby enhancing protein production. (C) Modiﬁed mRNAs are synthesized with
anti reverse cap analog (ARCA) and pseudouridine to increase stability. After transfection into cells or tissues, or injection into organs, protein is produced mostly from the
modiﬁed mRNA, but also from the endogenous mRNA.
296 H. Takahashi, P. Carninci / Biochemical and Biophysical Research Communications 452 (2014) 294–301translational start site of the Uchl1 mRNA [34]. Surprisingly, while
Uchl1-AS does not have any effect on the stability of the mRNA, it
up-regulates the translation of the UCHL1 protein. Distinct from
the region of overlap, AS-Uchl1 contains an inverted short inter-
spersed element (SINE) B2 repeat, which is transcribed in the anti-
sense orientation relative to the canonical sequence reported in the
FANTOM databases. Deletion mutant analysis revealed that both
the overlapping region and the SINEB2 region are essential to up-
regulate translation. This RNA, together with similar RNAs identi-
ﬁed in the study, are called SINEUPs, because they contain SINE
elements that UP-regulate protein translation (Fig. 1B). AS-Uchl1
works in signaling stress response. In MN9D cells treated with rap-
amycin, which inhibits the CAP-dependent translational pathway
through mammalian target of rapamycin (mTOR) and induces
stress response pathways, AS-Uchl1 is exported from the nucleus
to the cytosol, where it pairs with sense Uchl1 mRNA. This pairing
stimulates the interaction between the mRNA and actively trans-
lating polysomes, thereby increasing UCHL1 translation [34]. In
summary, in the cytosol SINEUPs can stimulate protein translation
from the mRNA with which they pair [34]. SINEUPs that are artiﬁ-
cially introduced by using overexpression vectors can simply stim-
ulate translation by speciﬁcally hybridizing to the 50 UTRs of target
mRNAs, as demonstrated for the reporter molecule, green ﬂuores-
cent protein [34]. Because SINEUPs can be designed to increase
translation of various mRNAs, it is theoretically possible to con-
struct a genome-wide resource by simply designing short overlap-
ping regions complementary to the 50 UTRs of all mammalian
mRNAs.
How many natural SINEUPs exist? In the ﬁrst bioinformatics
screening for AS RNAs carrying SINE elements in their non-overlap-
ping regions [34], about 100 potential SINEUPs were identiﬁed in
the mouse transcriptome. While the AS RNA that pairs withUxt-1 mRNA has been proven to be another true SINEUP, many
more candidates await experimental validation. We believe that
their cell or tissue speciﬁcity and strength may differ. Remarkably,
the SINEUPs that were discovered in the mouse are also effective in
human cells [34]. Because SINEB2 regions are not present in the
human genome, some conserved structure (rather than sequence)
is likely to be functional. This ﬁnding raises the fascinating ques-
tion of how speciﬁc non-conserved domains of mouse lncRNAs
can be functional in human and other mammalian cells (unpub-
lished observations). Perhaps there are structures that we have
not yet identiﬁed, which are conserved in apparently different
lncRNAs across different species. Human natural SINEUPs have
not yet been discovered; further studies are needed to fully clarify
the broadness and applicability of SINEUP technology in verte-
brates and beyond.4. AS RNA in viral pathogenesis
The active domains of SINEUPs originate from SINEB2 retro-
transposons, which include ancient retroviral elements and other
transposable, parasitic elements that have been integrated in the
genome, often to become symbiotic regulatory elements [34].
Non-coding RNA activity by viruses, and in particular retroviruses,
can still be observed in common parasites of living primate species.
Several reports suggest up-regulation of antisense RNAs after viral
infection [35–39]; some of these lncRNAs map to the opposite
strand of the 50 LTR, 30 LTR, or both of a virus genome and they
function to silence viral genome ampliﬁcation. One striking exam-
ple is the report that an HIV-1-encoded antisense lncRNA, which
localizes to the 50 LTR promoter region of the HIV-1 genome, works
as an epigenetic viral transcription regulator to suppress viral
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immunoprecipitation (ChIP) to investigate whether HIV-1-encoded
antisense lncRNA can epigenetically regulate viral transcription in
an HIV-1 latent T cell clone (ACH2). They discovered that HIV-1-
encoded antisense lncRNAs associate with DNA methyltransferase
3a (DNMT3a), causing destabilization of viral transcripts. Mecha-
nistic studies further revealed a role for the HIV-1-encoded anti-
sense lncRNA, together with small inhibitory RNAs, such as as154
or aspro5, which target the rev and ref regions, respectively, of
the antisense lncRNA. Inhibition of antisense transcripts resulted
in reduction of both the Enhancer of Zeste Homolog 2 (EZH2),
which is a polycomb-group protein that acts as a histone methyl-
transferase and histone deacetylase 1 (HDAC-1). These results
imply that binding of viral transcripts to the antisense lncRNA
may guide epigenetic silencing by directing the chromatin-remod-
eling protein complex to speciﬁc targets [36].
Another interesting example of a viral lncRNA is an AS RNA
expressed by human T-cell leukemia virus type 1 (HTLV-1).
HTLV-1 infection causes adult T-cell leukemia (ATL), a chronic dis-
ease of the spinal cord named HTLV-1-associated myelopathy, and
HTLV-1 uveitis [42,43]. The HTLV-1 genome expresses an antisense
HTLV-1 basic leucine zipper factor (HBZ) RNA, which can down-
regulate viral transcription, reduce leukemogenesis, and promote
T-lymphocyte proliferation [38,44–46]. HBZ RNA has two isoforms:
a spliced one (sHBZ) with two exons and an unspliced one (usHBZ)
with one exon, which produce polypeptides of different length
(206 and 209 amino acids, respectively). 50 RACE (Rapid Ampliﬁca-
tion of cDNA ends) experiments conﬁrmed that transcription start
sites are located in the ﬁrst exon of sHBZ, which resides in the U3-R
region of the 30 LTR of the HTLV-1 proviral genome [39,47]. Inter-
estingly, sHBZ expression is 4 times that of usHBZ in HTLV-1 carri-
ers and in ATL cases. This suggests that inhibition of the ﬁrst exon
of sHBZmight stop ATL cell proliferation, with important therapeu-
tic implications.
A third viral example is from the Sendai virus: when infecting
Namalwa cells, Sendai virus expresses an antisense lncRNA that
can stabilize human interferon-a1 mRNA by binding and seques-
tering a miRNA, via single-strand loop regions [31], creating a sort
of viral-derived miRNA–lncRNA sponge.
In summary, several viral-derived lncRNAs can speciﬁcally
modify the transcription, RNA stability, the epigenome and the
translation rate through various mechanisms. AS lncRNAs have
become attractive target for therapies because of their ability to
up- or down-tune regulatory networks already existing in the cells.5. Use of exogenous RNAs to interfere with cell programs
Utilization of AS RNAs as a tool to modify the activity of mRNAs
or even DNA has been very appealing for long time. Antisense
approaches present the theoretical advantage that target speciﬁc-
ity can simply be achieved by altering the sense-antisense
sequences. Unfortunately, many of the initial trials were not suc-
cessful due to a variety of issues, including difﬁculties in hitting
the target mRNAs due to secondary structures, and ineffective
sense-antisense pairing due to mRNA association with proteins
in vivo. Additionally, long sense-antisense RNAs can trigger an
interferon response [48], and efﬁcient delivery of nucleic acids in
the cells of a tissue or organ has been problematic [49]. Nonethe-
less, recent studies suggest that it is good time to revisit the ﬁeld
and address old challenges. In particular, there has been consider-
able activity in the biotech industry focusing on developing novel
RNA therapeutics: for example, AntagoNATs (OPKO-CURNA,
http://www.opko.com/therapeutics/opko-curna/; Fig. 1A), SINEUPs
(TransSINE technologies, http://www.transsine.com/; Fig. 1B), and
modiﬁed mRNA (Moderna, http://www.modernatx.com/, Fig. 1C).Wewill discuss some of the key events in the development of these
technologies and the current status of RNA-based therapy. Issues of
delivery are shared antisense lncRNAs, miRNAs, siRNAs, and other
artiﬁcial short AS RNAs. We will discuss some of these small RNAs,
to gain better understanding of the potential and challenges of
antisense therapies.
The classic genetic disorders, b-thalassemia, Duchenne
muscular dystrophy, and spinal muscular atrophy have been
successfully targeted with antisense oligonucleotides (AONs) to
either prevent or induce exon skipping [50,51]. Most exon-
skipping therapies in use today originated as AON therapies with
pre-mRNA as the target. AONs are designed to target splicing
sites to modify the structure of the mature mRNA. They act by
selecting speciﬁc exons, artiﬁcially designed pseudo exons, or
intra-exonic cryptic splice sites, generally to eliminate exons
containing nonsense mutations [52] For instance, by modifying
exon junctions, AONs can be used to produce antisense-induced
splicing variants that no longer contain premature stop codons
(i.e., stop codons upstream of the ﬁnal exon). This prevents non-
sense-mediated mRNA decay, a mechanism that detects and
degrades mRNAs containing premature stop codons [53], and
results in up-regulation of the mRNA transcript level, and produc-
tion of a protein that is at least partially functional (see the AON
review [54] for more details).
AONs should (1) be able to bind to speciﬁcally targeted mRNA
sequences; (2) be nuclease (e.g., RNaseH) resistant, especially for
pre-mRNA splicing strategies; (3) be deliverable into speciﬁc cells
and tissues; and (4) be safely metabolized. There have been many
efforts to chemically modify oligonucleotides to increase the sta-
bility of RNA binding and, most commonly, to improve nuclease
resistance. One important breakthrough has been the use of phosp-
horothioate-modiﬁed AONs [55]. A therapeutic phosphorothioate
AON, called Vitravene [56], was developed by ISIS Pharmaceuticals
in US as an antiviral agent against cytomegalovirus retinitis in AIDS
patients and gained US food and drug administration approval in
1998 [57]. Other phosphorothioate modiﬁcations have been intro-
duced into AONs: e.g., 20-O-methyl and 20-O-methoxyethyl groups;
these modiﬁcations show nuclease resistance and increased bind-
ing capacity to the target sequences [50,58]. Other chemically-
modiﬁed AONs, named phosphorodiamidate morpholino oligo-
mers (PMO), are a charge-neutral class of agents that have been
studied for their resistance to nucleases and proteinases, and their
ability to very efﬁciently inhibit translation of targeted mRNA by
steric blockage [59–61]. Comprehensive pharmacokinetic analysis
of PMOs has been reported in several species [59,62]. PMO have
been used successfully to inhibit viral mRNA translation, for exam-
ple in infection by the lethal ﬁloviruses, Ebola virus (EBOV) and
Marburg virus (MARV). Filovirus genomes (19 kb in length) con-
tain, in order, a 30-UTR, genes encoding nucleoproteins, VP35 and
VP40, genes encoding glycoproteins, VP30 and VP24, a gene encod-
ing RNA-dependent RNA polymerase (L protein), and a 50-UTR
[63,64]. EBOV and MARV are divergent in their genome sequence
and host tropism. EBOV-infected rhesus macaques (or rhesus mon-
keys; Macaca mulatta) were tested with PMOs whose antisense
sequences were speciﬁcally designed to bind to the VP35, VP24,
and L transcripts of EBOV. The combination of PMOs efﬁciently
blocked viral replication and protected 75% of the macaques from
lethal EBOV infection [65]. Additionally, PMO chemical modiﬁca-
tions that included conjugation with peptides of various lengths
and compositions were tested against VP24 in EBOV-infected cells
and mice [66]. Positively-charged PMOs (PMOplus) that are a com-
bination of EBOV-speciﬁc sequences (AVI-6002) or of MARV-spe-
ciﬁc sequences (AVI-6003) against VP24 and VP35 transcripts,
respectively, protected >60% of EBOV-infected rhesus macaques
and 100% of MARV-infected cynomolgus macaques (Macaca fascic-
ularis) by acting as speciﬁc virus replication inhibitors [67].
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they have the advantages of high speciﬁcity and effectiveness
[68]. Unfortunately, they are problematic because of their toxicity
[49]. Although some nucleic acids are too toxic for use in long-term
therapies, they may still play an extremely important role in short-
term approaches against infectious diseases; for instance, AONs
could be used to neutralize viruses during the peak of infection.
This could become particularly important in association with
next-generation sequencing, which will help to promptly identify
viral causative agents responsible for future pandemic infections.
Newly-discovered infectious agents could be coupled promptly to
antisense therapy because (a) the design of virus-neutralizing
AONs does not require an in depth understanding of the biological
mechanisms of viral infections, and (b) varying the antisense
sequences to compensate for virus mutations could cope well with
the problem of target variability. Changing the sequence of AONs is
likely to be much faster than developing novel conventional drugs
speciﬁc for mutated viral proteins.6. In search of stable expression
Due to the instability of RNAs, gene therapy using vectors (and
in particular viral vectors) to express RNAs has been attractive
because it is possible to provide stable, continuous expression of
therapeutic, native RNAs. However, other problems have arisen,
due mainly to the lack of control of insertion of expression vectors
into the genome. X-linked severe combined immunodeﬁciency (X-
SCID) is caused by mutation of the gene encoding the common
gamma chain (cc, also known as IL-2Rc), which is component of
receptors for interleukins (IL)-2, -4, -9, -11, -15, and -21. In X-SCID
patients, cc mutations block T-cell, B-cell, and NK-cell differentia-
tion. Mutations in the cc gene on chromosome X (X13q band) were
ﬁrst identiﬁed in an analysis of three X-SCID patients in 1993; all
three patients had different point mutations that caused prema-
ture stop codons in the cc gene [69]. In 1999, Cavazzana-Calvo
et al. [70] started the ﬁrst clinical trial for X-SCID gene therapy
with a Moloney murine leukemia virus-based retroviral vector
(MFG) containing cc cDNA under the control of the retroviral LTR
[71]. Following in vivo infusion of ex vivo-infected bone marrow
CD34+ cells, two patients, aged 11 months and 8 months, respec-
tively, showed increased T lymphocyte, including CD4+ and CD8+
subsets [72]. The cc protein was present on the membranes of T
cells in the second patient. Promising results prompted the exten-
sion of the clinical trial to additional patients; ultimately, treat-
ment helped 4 out of the total of 5 patients to live in normal
environmental conditions at least 4 years after gene therapy.
Unfortunately, one patient died from bacillus Calmette–Guerin
infection in early treatment even though T-cell immunity was par-
tially restored. Worryingly, another patient developed T-cell leuke-
mia resulting from unexpected insertion of therapeutic vector
sequence near the LMO2 gene [73]. In a subsequent second trial
in France, 9 out of the total of 10 patients were successfully treated
by gene therapy; however, 4 of these 9 patients developed T-cell
leukemia 31–68 months after gene therapy [74]. FDA put a hold
on the clinical trials in 2002 [75]. These patients also showed unex-
pected insertion of vector sequence [76], suggesting that alterna-
tive solutions that are not based on viral vectors are needed.7. Are RNA-based therapies feasible?
As discussed above, additional efforts are needed to develop
vectors that are incapable of inserting their genome into the host
genome, to (a) minimize the risk of mutation of important genes,
and (b) deliver RNA molecules directly into the target cells. Impor-
tant advances in this regard have come from the technologies usedto develop iPSCs; we believe that the production of iPSCs from
individual patients will become a fundamental tool for the next
generation of personalized medicine. Yamanaka and colleagues
ﬁrst created iPSCs by overexpressing KLF4, c-MYC, OCT4, and
SOX2 (KMOS), (known as the Yamanaka factors) with the use of
retroviral vectors [77,78]. As shown for X-SCID clinical trials, gene
therapies with viral vectors are not safe; in particular, the contin-
uous overexpression of these factors could be oncogenic. To safely
create iPSCs, Rossi and colleagues used modiﬁed mRNAs encoding
the four Yamanaka factors from human ESC-derived dH1f ﬁbro-
blasts, which display relatively efﬁcient viral mediated iPSC con-
version [79–81]. They synthesized mRNA from PCR templates by
using anti-reverse cap analog (30-O-Me-m7G[50]ppp[50]G), ATP,
GTP, 5-methyl cytidine triphosphate, and pseudouridine (Fig. 1C).
Phosphatase treatment slightly reduced the cytotoxicity upon
transfection. The combination of 5-methyl cytidine and pseudouri-
dine modiﬁcations was very important for reducing interferon
responses and toxicity to cells. Transfection and cell growth condi-
tions were optimized, while daily mRNA transfection was required
for high level expression of four Yamanaka factor mRNAs in dH1f
ﬁbroblast cells to properly initiate the reprogramming process to
produce iPSCs. Daily transfection was not further required during
the reprogramming process. Clearly, using modiﬁed mRNAs for
transfection to generate iPSCs (named RNA-induced pluripotent
stem cells [RiPSCs]) is highly effective and is safe compared with
the use of viral vectors. However, this process is relatively complex.
Kormann and colleagues successfully used modiﬁed mRNA
encoding mouse erythropoietin (EPO) in vitro and in vivo to stimu-
late red blood cell production [82]. Both in vitro and in vivo exper-
iments showed reduction of immune response and satisfactory
induction of expression of EPO when compared with un-modiﬁed
mRNA. Furthermore, therapeutic studies of regeneration of cardiac
tissues in a mouse myocardial infarction model have been per-
formed by using modiﬁed mRNA encoding human vascular endo-
thelial growth factor-A. [83].
Although long-term preservation of RNA expression is still a
potential issue, these studies suggest a broad feasibility of RNA-
based therapies. Developing such therapeutics is particularly
important when considering that there are 6000 rare diseases
[84] for which there is no existing therapy and no critical mass
of patients to pay for the cost of traditional drug development.
The biotechnology industry is quickly developing around these
areas. For instance, Moderna has been pioneering RNA therapies
based on modiﬁed mRNA technology. New regulations to facilitate
trials of treatments for rare diseases with RNA will be needed. To
expand the tools available, we believe that not only mRNAs, but
also lncRNAs and small RNAs should be considered. In this regard,
non-coding RNAs (miRNAs, SINEUPs) are particularly attractive
because they usually modulate the activity of mRNAs that are
already expressed in a given cell or tissue, and they have poten-
tially much higher speciﬁcity than mRNA overexpression technol-
ogies, which can cause ectopic protein expression in unintended
cells or tissues, with unpredictable consequences.8. We need to better understand RNA structures
Therapeutic AS RNAs including AONs should speciﬁcally bind
to target RNAs to produce double-stranded RNA. AS RNAs should
be designed to target a single-stranded, preferably looping region,
because strong stem-regions tend to react poorly with AS RNAs.
However, one major difﬁculty is accurately predicting the struc-
ture of the target mRNAs. Additionally, even if the structure can
be predicted or detected in vitro, the information may not be suf-
ﬁcient to predict the structure in vivo because the presence of
RNA-binding proteins can change the folding pattern. One
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netic resonance (NMR) analysis, but this technique can only be
used for RNAs that are no longer than 100 nt. Consequently,
structure determination of lncRNAs, which are in the order of
thousands of nucleotides in length, would require potentially
misleading analyses of separate segments of the RNA, followed
by the combination of separate structures and resolution of pos-
sible discrepancies. Although NMR is quite accurate for small
length of RNA, it is very laborious. A simpler approach to map-
ping secondary structures of RNAs is to use a predictive RNA sec-
ondary structure program, such as RNAfold [41] or CentroidFold
[85]. Such programs have been improved by the use of free
energy minimization algorithms. Mathews and colleagues
reported that RNA secondary structure prediction using such an
algorithm was successful in 73% of regions targeted by AS RNAs
[86]. Such programs are particularly useful when no other
options are available; however, they are limited by calculation
time and the very large number of predicted potential structures,
which may not necessarily reﬂect actual folding in vivo. Alterna-
tively, a recent and very promising approach is to digest folded
RNA with RNase V1 or S1 nucleases and to conduct sequencing
to detect single-stranded and double-stranded regions [87]. By
using this approach, a comprehensive map of the RNA secondary
structures of human lymphoblastoid cell RNA, taken from a
family trio (mother, father and their child) was produced;
AGO-bound target sites on the mRNA showed strong structural
accessibility from 1 to 3 nucleotides relative to the 50 end of
the miRNA-target site on the mRNA compared to predicted
targets not bound by AGO. An alternative to the double RNAse-
digestion approach consists of comprehensive chemical modiﬁca-
tion by dimethyl sulfate followed by sequencing analysis [88];
dimethyl sulfate is highly reactive towards single-stranded loop
regions of RNAs but unreactive towards highly structured stem
regions. This approach was validated by analyzing mRNAs of
known structure, HAC1, RPS28B and ASH1, from Saccharomyces
cerevisiae [89]. Like the double RNAse-digestion approach, the
dimethyl sulfate-sequencing approach has been used to distin-
guish single-stranded and double-stranded regions and provide
a draft genome-wide RNA structure map [90]. Although structure
may not be fully predicted by these approaches, we believe that
they provide a fundamental step towards RNA therapeutics, and
in particular antisense-based therapeutics, by providing compre-
hensive catalogs of single-stranded RNA targets [91].9. Perspectives
RNA is fast becoming a major target for cellular manipulations
and gene therapy. A particular important role will be played by
non-coding RNAs, because their large number and broad regula-
tory functions mean that they have the potential to provide a large
collection of regulatory tools. For instance, pre-mRNA and mRNA
can be targeted by using chemically-modiﬁed AONs, siRNA,
splice-switching oligonucleotides, translation-suppressing oligo-
nucleotides, or external guide sequences, as described in more
depth elsewhere [92]. Experience delivering these small RNAs
has helped in the development of delivery techniques that will
be useful for antisense lncRNAs, such as SINEUPs, antagoNATs, or
combinations of multiple types of lncRNAs. AS RNA approaches
are particularly promising because these RNAs often work as regu-
lators of speciﬁc existing mRNAs or genomic loci, which means
that they have the potential to increase the speciﬁcity of future
therapies and diminish side effects. In fact, where sense mRNAs
are not expressed, antisense lncRNAs are less likely to have an
effect because their natural mRNA target is absent. We can envis-
age the engineering of lncRNAs with multiple types of domains:one domain might carry sequences needed to pair speciﬁcally with
other nucleic acids (e.g., for triple-helix formation with genomic
DNA), and other domains could interact with speciﬁc proteins, tar-
geting them to speciﬁc loci; however, such non-coding RNA
domains are at the moment mostly unknown. Future studies to
determine RNA structures and identify functional domains are
needed to elucidate the world of regulatory RNAs. We anticipate
that there will be a research gold rush similar to that experienced
for protein research a decade ago.
We should remember that there is a lot of work ahead: there is
no ﬁnalized gene therapy tool as yet. Many technologies have their
drawbacks, with delivery and stability issues being the most difﬁ-
cult to overcome. RNA therapy should be broadly considered in
combination with different technologies or conventional drugs to
maximize synergistic effects and ﬁnd better therapeutic solutions.
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